- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
2024 Prediction from Melynda Barnes, M.D.
Melynda Barnes, M.D. is the Chief Medical Officer at Ro. She believes "more people will gain access to GLP-1 inhibitors" in 2024.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Melynda Barnes, M.D., said:
“Telehealth will be better than in-person care for certain chronic conditions. Telehealth offers a scalable solution to one of America’s most plaguing health challenges: obesity.
In 2024, more people will also access care for glucagon-like peptide 1 (GLP-1) inhibitors through direct-to-patient care than in-person providers. We’ll see more people turning to direct-to-patient care as new, more efficacious GLP-1s are introduced.
Employers that offer GLP-1s will poach and retain top talent. Employers that take this risk will reap the benefit of employees incentivized to stay. Survey data even show 44% of people would change jobs to access obesity treatment, and 51% would stay at a job they didn’t like to retain access to obesity treatment.”
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
